Clinical performance of antibodies to prothrombin and thrombin in Chinese patients with antiphospholipid syndrome: potential interest in discriminating patients with thrombotic events and non-thrombotic events
- 2 November 2016
- journal article
- biomarkers
- Published by Springer Nature in Rheumatology International
- Vol. 37 (4) , 579-584
Abstract
A hallmark feature of antiphospholipid syndrome (APS) is the presence of a wide spectrum of antiphospholipid antibodies. In this study, we evaluated the clinical relevance of antibodies to prothrombin (PT) (aPT) and thrombin (aThr) in Chinese patients with APS. A total of 229 subjects were tested, including 86 patients with APS [35 patients with primary APS (PAPS), 51 patients with APS associated with other diseases (APSAOD)], 104 patients with non-APS diseases (disease controls), and 39 healthy controls. Serum IgG/IgM/IgA aPT and aThr were determined by ELISA. The levels of both IgG/IgM/IgA aPT and IgG/IgM/IgA aThr were significantly increased in patients with PAPS and APSAOD compared with patients with non-APS thrombosis and non-APS PRM, and HC. Both IgG aPT and IgG aThr exhibited promising diagnostic potentials for APS with sensitivities and specificities of 16.3 and 95.8% (IgG aPT), and 19.8 and 99.3% (IgG aThr), respectively. Importantly, both IgG aPT (OR 4.06; 95% CI 1.49–11.05) and IgG aThr (OR 4.49; 95% CI 1.62–12.45) were significantly correlated with arterial, but not venous, thrombotic events. Our findings highlighted that IgG aPT and IgG aThr could serve as promising biomarkers to identify patients at risk of arterial thrombosis in China.Keywords
Funding Information
- National Natural Science Foundation of China (81302592, 81373188, 81172857)
This publication has 19 references indexed in Scilit:
- Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndromeThrombosis and Haemostasis, 2014
- The thrombophilic network of autoantibodies in celiac diseaseBMC Medicine, 2013
- The clinical significance of autoantibodies directed against prothrombin in primary antiphospholipid syndromeClinica Chimica Acta, 2012
- Antiphospholipid syndromeThe Lancet, 2010
- Identification of anti-prothrombin antibodies in the anti-phospholipid syndrome that display the prothrombinase activityRheumatology, 2009
- A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E‐selectin on endothelial cellsBritish Journal of Haematology, 2006
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Identification of Thrombin Antibodies in Patients with Antiphospholipid SyndromeAnnals of the New York Academy of Sciences, 2005
- Anti-prothrombin antibodies as a potential risk factor of recurrent venous thromboembolismThrombosis and Haemostasis, 2004
- Anti–β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndromeBlood, 2003